natgillin/translations-raw huggingface dataset:
Retacrit therapy should continue until one month after the end of chemotherapy.
S terapijo z zdravilom Retacrit moramo nadaljevati še en mesec po zaključku kemoterapije.
A less defined profile was observed for RBCs and haemoglobin.
Manj definiran profil so opazili pri eritrocitih in hemoglobinu.
A maximum volume of 1 mL at one injection site should generally not be exceeded.
Na mestu injiciranja se v splošnem ne sme dajati volumen večji kot 1 ml.
Autologous predonation programme
Avtologni preddonorski program
Retacrit and other products that stimulate red cell production may increase the risk of developing blood clots in all patients.
Zdravilo Retacrit in druga zdravila, ki spodbujajo tvorbo rdečih krvnih celic, lahko pri vseh bolnikih povečajo tveganje za nastanek krvnih strdkov.
If you are taking a medicine called cyclosporin (used e.g. after kidney transplants), your doctor may order blood tests to check the level of cyclosporin while you are taking Retacrit.
Če jemljete zdravilo, imenovano ciklosporin (uporablja se npr. po presaditvi ledvic), vam bo zdravnik morda predpisal teste krvi, s katerimi bo med jemanjem zdravila Retacrit preveril koncentracijo ciklosporina.
The prefilled syringes contain between 0.3 and 1 ml solution, depending on the content of epoetin zeta (see “What Retacrit contains”).
Napolnjene injekcijske brizge vsebujejo med 0,3 in 1 ml raztopine, odvisno od vsebnosti epoetina zeta (glejte "Kaj vsebuje zdravilo Retacrit").
• if any liquid has leaked out of the pre-filled syringe or condensation is visible within the sealed blister,
• če je iz vnaprej napolnjene brizge iztekla tekočina ali če je v zavarjenem blistru videti kondenzacijo,
If signs and symptoms suggestive of these reactions appear, Retacrit should be withdrawn immediately and an alternative treatment considered.
Če se pojavijo znaki in simptomi, ki kažejo na te reakcije, je treba zdravljenje z zdravilom Retacrit takoj prekiniti in razmisliti o drugi vrsti zdravljenja.
Retacrit is one of a group of products that stimulate the production of red blood cells, like the human protein erythropoietin does.
Retacrit je eno izmed zdravil, ki spodbuja nastajanje rdečih krvnih celic, kakor jo spodbuja človeška beljakovina eritropoetin.
• Retacrit is given by injection under the skin each week for three weeks before surgery and on the day of surgery.
• Zdravilo Retacrit se daje z injekcijo pod kožo vsak teden, z začetkom tri tedne pred kirurškim posegom in na dan kirurškega posega.
For the purpose of ambulatory use, the medicinal product may be taken out of the refrigerator, without being replaced, for a maximum period of 3 days at a temperature not above 25°C.
Pri ambulantni uporabi lahko zdravilo vzamete iz hladilnika, ne da bi ga zamenjali, in ga nato hranite največ 3 dni pri sobni temperaturi, ki ne presega 25 ºC.
The studies either recruited patients who were being treated with chemotherapy (two studies) or used patient populations in which ESAs are not indicated: anaemia in patients with cancer not receiving chemotherapy, and head and neck cancer patients receiving radiotherapy.
V študije so vključili bolnike, ki so bili deležni kemoterapije (dve študiji) ali pa so uporabljali populacije bolnikov, pri katerih zdravila za stimulacijo eritropoeze niso bila indicirana: anemija pri bolnikih z rakom, ki ne prejemajo kemoterapije ter bolniki z rakom glave in vratu, ki prejemajo terapijo z obsevanjem.
In animal studies, epoetin alfa has been shown to decrease foetal body weight, delay ossification and increase foetal mortality when given in weekly doses of approximately 20 times the recommended human weekly dose.
Študije na živalih so pokazale, da epoetin alfa zmanjšuje telesno maso ploda, zakasni osifikacijo in povečuje smrtnost pri plodih, če se ga daje v tedenskih odmerkih, ki so približno dvajsetkratna vrednost priporočenega tedenskega odmerka za ljudi.
• Retacrit is given by injection under the skin.
• Zdravilo Retacrit dajemo z injiciranjem pod kožo.
This medicine contains phenylalanine and may be harmful for people with phenylketonuria (genetic enzyme deficiency that increases excretion of a chemical (phenylketone) in urine and may cause nervous system disorders).
To zdravilo vsebuje fenilalanin, ki lahko škoduje ljudem s fenilketonurijo (dedno pomanjkanje encima, ki zvišuje izločanje spojine (fenilketona) v seč in ki lahko povzroči bolezni živčnega sistema).
The recommended maintenance dose is between 25 IU/kg and 50 IU/kg, 2 times per week in 2 equal injections.
Priporočeni vzdrževalni odmerek je med 25 i.e./kg in 50 i.e./kg dvakrat tedensko v dveh enakih injekcijah.
The most frequently occurring adverse drug reactions observed in clinical trials of epoetin alfa are diarrhoea, nausea, vomiting, pyrexia and headache.
Najpogostejši neželeni učinki zdravila, ki so se pojavili v kliničnih preskušanjih z epoetinom alfa, so diareja, navzea, bruhanje, pireksija in glavobol.
If the patient has developed a severe cutaneous skin reaction such as SJS or TEN due to the use of Retacrit, treatment with Retacrit must not be restarted in this patient at any time.
Če je pri bolniku zaradi uporabe zdravila Retacrit prišlo do hude kožne reakcije, kot sta SJS ali TEN, zdravljenja z zdravilom Retacrit ni dovoljeno ponovno začeti.
On average, patients treated with epoetin alfa were able to predeposit significantly more units of blood (4.5 units) than placebo-treated patients (3.0 units).
Povprečno so lahko bolniki, ki so se zdravili z epoetinom alfa, deponirali pomembno več enot krvi (4,5 enote) v primerjavi z bolniki, ki so prejemali placebo (3,0 enote).
Retacrit is presented as a clear and colourless solution for injection in a pre-filled syringe with a fixed injection needle.
Zdravilo Retacrit je bistra in brezbarvna raztopina za injiciranje v napolnjenih injekcijskih brizgah s fiksno injekcijsko iglo.
If epoetin zeta is given concomitantly with cyclosporin, blood levels of cyclosporin should be monitored and the dose of cyclosporin adjusted as the haematocrit rises.
Če se uporablja epoetin zeta hkrati s ciklosporinom, je treba nadzorovati koncentracije ciklosporina v krvi in odmerek ciklosporina prilagajati s porastom hematokrita.
Clinical data with subcutaneous administration in children are limited.
Klinični podatki o subkutanem injiciranju pri otrocih so omejeni.
The greatest effects are observed in patients with low haemoglobin (≤ 13 g/dL; 8.1 mmol/L).
Največje učinke so opazili pri bolnikih z nizko koncentracijo hemoglobina (≤ 13 g/dl; 8,1 mmol/l).
Dose should not be increased over the maximum of 1 050 IU/kg (total dose 80 000 IU) per week.
Odmerka ne smemo povečati toliko, da bi presegel največji odmerek 1.050 i.e./kg (skupni odmerek 80.000 i.e.) na teden.
Do not double up the injections to make up for a forgotten dose.
Injekcij ne podvajajte, če ste pozabili vzeti prejšnji odmerek.
Please discuss with your doctor.
Posvetujte se z zdravnikom.
OUTER LABEL (WITH BLUE BOX) MULTIPACK
ZUNANJA NALEPKA (S PODATKI ZA BLUE BOX), SKUPNO PAKIRANJE
The safety and efficacy of Retacrit in chronic renal failure patients with anaemia before initiation of dialysis or on peritoneal dialysis have not been established.
Varnost in učinkovitost zdravila Retacrit pri bolnikih s kronično ledvično okvaro z anemijo pred začetkom dialize ali na peritonealni dializi nista bili dokazani.
• If you are having dialysis treatment when you begin treatment with Retacrit, your dialysis regime may need to be adjusted.
• Če ste ob začetku zdravljenja z zdravilom Retacrit na dializi, bo mogoče treba popraviti vaš urnik dializ.
In all patients, haemoglobin levels should be closely monitored due to a potential increased risk of thromboembolic events and fatal outcomes when patients are treated at haemoglobin levels above the concentration range for the indication of use.
Pri vseh bolnikih je treba skrbno spremljati ravni hemoglobina zaradi možnega povečanega tveganja za pojav trombemboličnih dogodkov in smrtnega izida pri bolnikih, ki jih zdravijo pri ravneh hemoglobina, ki presegajo razpon koncentracije za posamezno indikacijo.
• Grasp the tip of the plastic needle catcher and bend it away from needle cover.
• Primite vrh plastičnega varovalnega nastavka in ga upognite vstran od pokrovčka igle.
Overall, based on the results of these pharmacodynamic studies in healthy subjects, the 40 000 IU once-weekly dosing regimen seems to be more efficient in producing RBCs than the biweekly regimens despite an observed similarity in reticulocyte production in the once-weekly and biweekly regimens.
Na podlagi rezultatov teh farmakodinamičnih študij pri zdravih preskušancih na splošno kaže, da je režim odmerjanja 40.000 i.e. enkrat na teden bolj učinkovit pri tvorbi rdečih krvničk kot režim enkrat na dva tedna, kljub opaženi podobnosti pri tvorbi retikulocitov pri režimih enkrat na teden in enkrat na dva tedna.
Epoetin alfa has been studied in clinical trials in adult anaemic cancer patients with lymphoid and solid tumors, and patients on various chemotherapy regimens, including platinum and non-platinum-containing regimens.
Epoetin alfa so preučevali v kliničnih preskušanjih pri odraslih anemičnih bolnikih z rakom z limfomi in čvrstimi tumorji ter pri bolnikih na različnih režimih kemoterapije, vključno z režimi, ki vsebujejo platino, in tistimi, ki ne vsebujejo platine.
The maximum dosage should not exceed 150 IU/kg 3 times per week, 240 IU/kg (up to a maximum of 20 000 IU) once weekly, or 480 IU/kg (up to a maximum of 40 000 IU) once every 2 weeks.
Največji odmerek ne sme preseči 150 i.e./kg trikrat na teden, 240 i.e./kg (do največ 20.000 i.e.) enkrat tedensko ali 480 i.e./kg (do največ 40.000 i.e.) enkrat na dva tedna.
Patients treated with epoetin alfa were also able to predeposit significantly more units of blood (epoetin alfa 300 IU/kg = 4.4 units; epoetin alfa 600 IU/kg = 4.7 units) than placebo-treated patients (2.9 units).
Bolniki, ki so se zdravili z epoetinom alfa, so lahko deponirali pomembno več enot krvi (epoetin alfa 300 i.e./kg = 4,4 enote; epoetin alfa 600 i.e./kg = 4,7 enote) v primerjavi z bolniki, ki so prejemali placebo (2,9 enote).
In order to ensure optimum response to epoetin zeta, adequate iron stores should be assured and iron supplementation should be administered if necessary (see section 4.2):
Da je odziv na epoetin zeta optimalen, je treba poskrbeti za ustrezne zaloge železa in po potrebi dodajati dodatke z železom (glejte poglavje 4.2):
If you are given a product in this group other than Retacrit during your treatment, speak to your doctor or pharmacist before using it.
Če med zdravljenjem prejmete drugo zdravilo iz te skupine, ki ni zdravilo Retacrit, se pred uporabo tega zdravila posvetujte z zdravnikom ali farmacevtom.
In children the haemoglobin level should be maintained between 9.5 and 11 g/dL.
Pri otrocih je treba raven hemoglobina vzdrževati med 9,5 in 11 g/dl.
Epoetin alfa 600 IU/kg (administered intravenously or subcutaneously once weekly) has been evaluated in a randomised, double-blind, placebo-controlled, 16-week study and in a randomised, controlled, open-label, 20-week study in anaemic paediatric patients receiving myelosuppressive chemotherapy for the treatment of various childhood non-myeloid malignancies.
Epoetin alfa 600 i.e./kg (ki so ga injicirali intravensko ali subkutano enkrat na teden) so ocenili v randomizirani, dvojno slepi, s placebom nadzorovani 16-tedenski študiji in v randomizirani, nadzorovani, odprti 20-tedenski študiji pri anemičnih pediatričnih bolnikih, ki so prejemali mielosupresivno kemoterapijo za zdravljenje različnih otroških nemieloičnih malignih obolenj.
• after the expiry date on the label and outer carton
• po izteku roka uporabnosti, navedenega na etiketi in zunanji ovojnini;
Once the haemoglobin level is <11 g/dL the dose can be restarted on the same dosing step or one dosing step down based on physician judgement.
Ko je raven hemoglobina < 11 g/dl, lahko nadaljujete zdravljenje z enakim odmerkom ali za en korak manjšim odmerkom, odvisno od presoje zdravnika.
Mildly anaemic patients (haematocrit of 33 to 39%) requiring predeposit of ≥ 4 units of blood should be treated with Retacrit 600 IU/kg intravenously, 2 times per week for 3 weeks prior to surgery.
Blago anemičnim bolnikom (hematokrit od 33 do 39 %), ki potrebujejo zalogo ≥ 4 enote krvi, je treba dajati zdravilo Retacrit v odmerku 600 i.e./kg intravensko, dvakrat na teden, 3 tedne pred operacijo.
In female adult patients with metastatic breast cancer, subcutaneous co-administration of 40 000 IU/mL epoetin alfa with trastuzumab 6 mg/kg had no effect on the pharmacokinetics of trastuzumab.
Pri odraslih bolnicah z metastatskim rakom dojk sočasno subkutano injiciranje 40.000 i.e./ml epoetina alfa in 6 mg/kg trastuzumaba ni vplivalo na farmakokinetiko trastuzumaba.
Retacrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): o in adults and paediatrics aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis (see section 4.4).
Zdravilo Retacrit je indicirano za zdravljenje simptomatske anemije, povezane s kronično ledvično odpovedjo: o pri odraslih in pediatrični populaciji, stari od 1 do 18 let na hemodializi ali odraslih bolnikov na peritonealni dializi (glejte poglavje 4.4).
Retacrit has no or negligible influence on the ability to drive and use machines.
Zdravilo Retacrit nima ali ima zanemaljiv vpliv na sposobnost vožnje in upravljanja strojev.
Following intravenous administration of erythropoietin in subjects with chronic renal failure, the volume of distribution ranged from 57-107 mL/kg after single dosing (12 IU/kg) to 42-64 mL/kg after multiple dosing (48-192 IU/kg), respectively.
Po intravenskem dajanju eritropoetina pri bolnikih s kronično ledvično odpovedjo je bil razpon volumna porazdelitve od 57-107 ml/kg po enkratnem odmerjanju (12 i.e./kg) do 42-64 ml/kg po večkratnem odmerjanju (48-192 i.e./kg).
How to inject yourself using a pre-filled syringe
Kako si sami injicirate zdravilo z uporabo napolnjene injekcijske brizge
A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin zetaand perform anti-erythropoietin antibody testing.
Paradoksalno zmanjšanje koncentracije hemoglobina in pojav hude anemije, povezane z majhnim številom retikulocitov, pomeni, da je treba zdravljenje z epoetinom zeta prekiniti takoj in opraviti testiranje za protitelesa proti eritropoetinu.
The effect of epoetin alfa in facilitating autologous blood donation in patients with low haematocrits (≤ 39% and no underlying anaemia due to iron deficiency) scheduled for major orthopaedic surgery was evaluated in a double-blind, placebo-controlled study conducted in 204 patients, and a single-blind placebo controlled study in 55 patients.
Učinek epoetina alfa na izboljšanje avtolognega darovanja krvi pri bolnikih z majhnimi vrednostmi hematokrita (≤ 39% in brez osnovne anemije zaradi pomanjkanja železa), ki so imeli načrtovan večji ortopedski kirurški poseg, so ocenjevali v dvojno slepi, s placebo nadzorovani študiji, ki so jo izvedli pri 204 bolnikih, in v enojno slepi, s placebom nadzorovani študiji pri 55 bolnikih.
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13 933 patients) and for the cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10 441 patients).
Metaanaliza podatkov o celotnem preživetju bolnikov daje oceno stopnje tveganja 1,06 v prid kontrolni skupini (95 % CI: 1,00; 1,12; 53 preskušanj in 13.933 bolnikov), za bolnike z rakom, ki so dobivali kemoterapijo, je bila stopnja tveganja za celotno preživetje 1,04 (95 % CI: 0,97; 1,11; 38 preskušanj in 10.441 bolnikov).
Tell your doctor or nurse immediately if you are aware of any of these effects, or if you notice any other effects while you are receiving treatment with Retacrit.
Zdravniku ali medicinski sestri nemudoma povejte, če opazite kateregakoli od teh neželenih učinkov ali če med zdravljenjem z zdravilom Retacrit opazite druge neželene učinke.
A major cardiovascular event (death, myocardial infarction, stroke or hospitalization for congestive heart failure) occurred among 125 (18%) of the 715 patients in the higher haemoglobin group compared to 97 (14%) among the 717 patients in the lower haemoglobin group (hazard ratio [HR] 1.3, 95% CI: 1.0, 1.7, p = 0.03).
Večji kardiovaskularni dogodek (smrt, miokardni infarkt, možganska kap ali hospitalizacija zaradi kongestivnega srčnega popuščanja) se je pojavil pri 125 (18 %) od 715 bolnikov v skupini z višjo koncentracijo hemoglobina v primerjavi s 97 (14 %) od 717 bolnikov v skupini z nižjo koncentracijo hemoglobina (razmerje ogroženosti [HR - hazard ratio] 1,3; 95 % IZ: 1,0; 1,7; p = 0,03).
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section
Metaanaliza dosledno kaže tudi na statistično pomembno zvečanje relativnega tveganja za pojav tromboemboličnih dogodkov pri bolnikih z rakom, ki prejemajo rekombinantni humani eritropoetin (glejte poglavje 4.4).
Chronic renal failure
Kronična ledvična okvara
No data on the effects of epoetin zeta on fertility are available.
Podatki o vplivu epoetina zeta na plodnost niso na voljo.
The safety and efficacy of epoetin alfa in paediatrics have not been established.
Varnost in učinkovitost epoetina alfa pri otrocih nista bili dokazani.
Tell your doctor or nurse immediately if you notice any of the effects in this list.
Takoj obvestite zdravnika ali medicinsko sestro, če opazite kateregakoli izmed naštetih učinkov.
All other causes of anaemia (iron, folate or Vitamin B12 deficiency, aluminium intoxication, infection or inflammation, blood loss, haemolysis and bone marrow fibrosis of any origin) should be evaluated and treated prior to initiating therapy with epoetin zeta, and when deciding to increase the dose.
Vse druge vzroke anemije (pomanjkanje železa, folne kisline ali vitamina B12, zastrupitev z aluminijem, okužba ali vnetje, izguba krvi, hemoliza in fibroza kostnega mozga kateregakoli izvora) je treba oceniti oziroma zdraviti pred začetkom zdravljenja z epoetinom zeta in pri odločanju o povečanju odmerka.
Patients were stratified according to their baseline haemoglobin (≤ 10 g/dL, >10 to ≤ 13 g/dL and >13 g/dL).
Bolnike so stratificirali glede na njihovo izhodiščno vrednost hemoglobina (≤ 10 g/dl, > 10 do ≤ 13 g/dl in > 13 g/dl).
Diarrhoea, Nausea, Vomiting Very common
Bolezni prebavil driska, navzea, bruhanje zelo pogosti
Retacrit contains phenylalanine
Zdravilo Retacrit vsebuje fenilalanin
• have severe disorders of the veins and arteries
• imate hude motnje krvnega obtoka v venah in arterijah,
Do not use Retacrit:
Zdravila Retacrit ne smete uporabljati:
Epoetin alfa 300 IU/kg significantly reduced the risk of allogeneic transfusion in patients with a pretreatment haemoglobin of >10 to ≤13 g/dL.
Epoetin alfa 300 i.e./kg je pomembno zmanjšal tveganje za alogensko transfuzijo krvi pri bolnikih z vrednostmi hemoglobina pred zdravljenjem > 10 do ≤ 13 g/dl.
Adults with myelodysplastic syndrome
Odraslih z mielodisplastičnim sindromom
Treatment should only be given to patients with moderate anaemia (haemoglobin [Hb] concentration range between 10 to 13 g/dL [6.2 to 8.1 mmol/L], no iron deficiency) if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).
Tovrstno zdravljenje smemo predpisati samo bolnikom z zmerno anemijo (razpon koncentracije hemoglobina [Hb] med 10 in 13 g/dl [od 6,2 do 8,1 mmol/l], brez pomanjkanja železa), kadar postopki za zmanjšanje izgube krvi niso na razpolago ali če ne zadoščajo za načrtovani večji kirurški poseg, pri katerem je potrebna večja količina krvi (4 ali več enot krvi za ženske oz. 5 ali več enot za moške)
For cancer patients, iron supplementation (elemental iron 200 to 300 mg/day orally) is recommended if transferrin saturation is below 20%.
Pri bolnikih z rakom se priporoča dodajanje železa (elementarno železo 200 do 300 mg/dan peroralno), če je nasičenost transferina pod 20%.
You may take Retacrit out of the refrigerator and keep it at room temperature (up to 25°C) for no longer than 3 days.
Zdravilo Retacrit lahko vzamete iz hladilnika in ga hranite pri sobni temperaturi (do 25 °C), vendar največ 3 dni.
If you develop a serious rash or another of these skin symptoms, stop taking Retacrit and contact your doctor or seek medical attention immediately.
Če se je pri vas pojavil hud izpuščaj ali eden od teh kožnih simptomov, prenehajte z jemanjem zdravila Retacrit in se takoj posvetujte z zdravnikom ali poiščite zdravniško pomoč.
The aim of treatment is to maintain your haemoglobin level between 10 and 12 g/dL as a higher haemoglobin level may increase the risk of blood clots and death.
Namen zdravljenja je ohranjati vašo raven hemoglobina med 10 in 12 g/dl, saj višje ravni hemoglobina lahko povečajo tveganje za krvne strdke in smrt.
After single doses (20 000 to 160 000 IU subcutaneously) of epoetin alfa, a dose-dependent response was observed for the pharmacodynamic markers investigated including: reticulocytes, RBCs, and haemoglobin.
Po enkratnem odmerjanju (20.000 do 160.000 i.e. subkutano) epoetina alfa so opazili od odmerka odvisen odziv preučevanih farmakodinamičnih kazalcev, vključno z retikulociti, eritrociti in hemoglobinom.
Patients were assigned to epoetin alfa treatment targeting a maintenance haemoglobin level of 13.5 g/dL (higher than the recommended haemoglobin concentration level) or 11.3 g/dL.
Bolnike so razporedili na zdravljenje z epoetinom alfa s ciljem ohranjati raven hemoglobina 13,5 g/l (nad priporočeno koncentracijo hemoglobina) ali 11,3 g/l.
In order to ensure optimum response to epoetin zeta, adequate iron stores should be assured and iron supplementation should be administered if necessary (see section 4.4).
Da je odziv na epoetin zeta optimalen, je treba poskrbeti za ustrezne zaloge železa in po potrebi dodajati železo (glejte poglavje 4.4).
In a prospective, randomised, double-blind, placebo-controlled trial conducted in 375 anaemic patients with various non-myeloid malignancies receiving non-platinum chemotherapy, there was a significant reduction of anaemia-related sequelae (e.g. fatigue, decreased energy, and activity reduction), as measured by the following instruments and scales: Functional Assessment of Cancer TherapyAnaemia (FACT-An) general scale, FACT-An fatigue scale, and Cancer Linear Analogue Scale (CLAS).
V prospektivnem, randomiziranem, dvojno slepem s placebom kontroliranem preskušanju so pri 375 slabokrvnih bolnikih z različnimi nemieloidnimi malignostmi, ki so prejemali kemoterapijo brez platine, ugotovili signifikantno zmanjšanje z anemijo povezanih posledic (npr. utrujenosti, zmanjšane energije in zmanjšane aktivnosti), kot se jih meri s pomočjo naslednjih instrumentov in meril: splošna merila za funkcionalno oceno terapije raka - anemija (FACT-An - ''Functional Assessment of Cancer Therapy-Anaemia''), FACT-An merila utrujenosti, in linearna analogna skala za rak (CLAS - ''Cancer
Epoetin zeta is not approved in the management of anaemia associated with hepatitis C.
Epoetin zeta ni odobren za zdravljenje anemije, povezane s hepatitisom C.
In studies to explore extending the dosing interval (40 000 IU once weekly and 80 000, 100 000, and 120 000 IU biweekly), a linear but non-dose-proportional relationship was observed between mean Cmax and dose, and between mean AUC and dose at steady state.
V študijah, v katerih so preučevali podaljšanje intervala odmerjanja (40.000 i.e. enkrat na teden ter 80.000, 100.000 in 120.000 i.e. vsaka dva tedna), so opazili z odmerkom nesorazmerno linearno razmerje med povprečno vrednostjo Cmax in odmerkom ter med povprečno vrednostjo AUC in odmerkom v stanju dinamičnega ravnovesja.